Atossa Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
(Z)-endoxifen, a differentiated breast cancer therapy, shows reduced side effects and strong efficacy in both prevention and metastatic settings. Key trials are ongoing, with regulatory filings and major data readouts expected over the next year.
-
(Z)-endoxifen is positioned as a differentiated therapy for ER-positive breast cancer, showing strong efficacy, safety, and broad clinical utility from prevention to metastatic disease. The company is advancing toward an FDA registration trial in the metastatic setting, supported by robust financials and IP.
-
(Z)-endoxifen is positioned as a next-generation therapy for ER+ breast cancer, with strong efficacy, safety, and broad clinical utility. The company is prioritizing metastatic approval, advancing global trials, and maintains a robust financial and operational foundation.
Fiscal Year 2024
-
Advanced Z-endoxifen in metastatic breast cancer, supported by strong clinical data and improved financials, with a focus on U.S. FDA approval in 2025 and a robust cash position to fund ongoing trials. Clinical milestones and regulatory engagement remain key priorities.
-
Focused on (Z)-endoxifen for breast cancer, the company is advancing six phase II trials with key data readouts expected by year-end and into 2025. Strong cash reserves support ongoing development, and new FDA guidelines on breast density highlight the market opportunity.
-
(Z)-endoxifen, a potent SERM/SERD, shows promise in reducing breast density and treating HR-positive, HER2-negative breast cancer with fewer side effects than tamoxifen. Key data from ongoing trials, including density reduction and higher-dose cancer cohorts, are expected by early 2025.
-
Endoxifen is advancing through multiple phase II trials for breast cancer prevention and treatment, with promising early results and a strong financial position supporting ongoing research. AI-driven studies are expanding its potential indications, and strategic partnerships are being considered for broader market reach.